Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw

International Journal of Oral and Maxillofacial Surgery

Volumn 40, Issue 6, 2011, Pages 605-611

  Katz, J ^a   Gong, Y ^b   Salmasinia, D ^c   Hou, W ^d   Burkley, B ^b   Ferreira, P ^b   Casanova, O ^b   Langaee, T Y ^b   Moreb, J S ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Bisphosphonates; Genetic polymorphisms; Multiple myeloma; Osteonecrosis of the jaw (ONJ); Pharmacogenomics

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTOCHROME P450 2C8; GELATINASE A; OSTEOPONTIN; OSTEOPROTEGERIN; PREDNISONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; THALIDOMIDE; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BISPHOSPHONATE INDUCED OSTEONECROSIS OF THE JAW; BONE DENSITY; BONE METABOLISM; CLINICAL STUDY; COHORT ANALYSIS; COL1A1 GENE; DEMOGRAPHY; DIABETES MELLITUS; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PERIODONTITIS; POLYMERASE CHAIN REACTION; RACE; RISK FACTOR; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT DURATION;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; GENE FREQUENCY; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; OSTEOPONTIN; OSTEOPROTEGERIN; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RISK FACTORS; SMOKING; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79956286289     PISSN: 09015027     EISSN: 13990020     Source Type: Journal    
DOI: 10.1016/j.ijom.2011.02.002     Document Type: Article

References (29)

1. ALVAREZ E, WESTMORE M, GALVIN RJ, CLAPP CL, CONSIDINE EL, SMITH SJ, KEYES K, IVERSEN PW, DELAFUENTE DM, SULAIMON S, ZAMBRANO C, MA L, SATO M, MARTIN TJ, TEICHER BA, GALBREATH EJ. Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption. Clin Cancer Res 2003: 9: 5705-5713.
2. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007: 65: 369-376.
3. ASANO T, TAKAHASHI KA, FUJIOKA M, INOUE S, OKAMOTO M, SUGIOKA N, NISHINO H, TANAKA T, HIROTA Y, KUBO T. Abcb1 c3435t and g2677t/a polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 2003: 13: 675-682.
4. ASSOULINE-DAYAN Y, CHANG C, GREENSPAN A, SHOENFELD Y, GERSHWIN ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002: 32: 94-124.
5. BJORKMAN A, BURTSCHER IM, SVENSSON PJ, HILLARP A, BESJAKOV J, BENONI G. Factor v leiden and the prothrombin 20210a gene mutation and osteonecrosis of the knee. Arch Orthop Trauma Surg 2005: 125: 51-55.
6. BOYDE A, TRAVERS R, GLORIEUX FH, JONES SJ. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int 1999: 64: 185-190.
7. DALY AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010: 11: 241-246.
8. EDWARDS BJ, GOUNDER M, MCKOY JM, BOYD I, FARRUGIA M, MIGLIORATI C, MARX R, RUGGIERO S, DIMOPOULOS M, RAISCH DW, SINGHAL S, CARSON K, OBADINA E, TRIFILIO S, WEST D, MEHTA J, BENNETT CL. Pharmacovigilance and reporting oversight in us fda fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008: 9: 1166-1172.
9. GIACOPELLI F, MARCIANO R, PISTORIO A, CATARSI P, CANINI S, KARSENTY G, RAVAZZOLO R. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 2004: 20: 87-96.
10. GRANT SF, REID DM, BLAKE G, HERD R, FOGELMAN I, RALSTON SH. Reduced bone density and osteoporosis associated with a polymorphic sp1 binding site in the collagen type i alpha 1 gene. Nat Genet 1996: 14: 203-205.
11. HSU YH, NIU T, TERWEDOW HA, XU X, FENG Y, LI Z, BRAIN JD, ROSEN CJ, LAIRD N, XU X. Variation in genes involved in the rankl/rank/opg bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Hum Genet 2006: 118: 568-577.
12. KATHIRESAN S, MELANDER O, ANEVSKI D, GUIDUCCI C, BURTT NP, ROOS C, HIRSCHHORN JN, BERGLUND G, HEDBLAD B, GROOP L, ALTSHULER DM, NEWTON-CHEH C, ORHO-MELANDER M. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008: 358: 1240-1249.
13. KATZ J, GEORGE T, SANDOW P, MACHADO M, DICKERSON L, MOREB JS. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes. J Support Oncol 2009: 7: 9-10.
14. KHAMAISI M, REGEV E, YAROM N, AVNI B, LEITERSDORF E, RAZ I, ELAD S. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2006.
15. KOH JM, PARK BL, KIM DJ, KIM GS, CHEONG HS, KIM TH, HONG JM, SHIN HI, PARK EK, KIM SY, SHIN HD. Identification of novel rank polymorphisms and their putative association with low bmd among postmenopausal women. Osteoporos Int 2006.
16. LANGAEE T, RONAGHI M. Genetic variation analyses by pyrosequencing. Mutat Res 2005: 573: 96-102.
17. LEE YH, WOO JH, CHOI SJ, JI JD, SONG GG. Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis. Mol Biol Rep 2010: 37: 227-234.
18. LEHRER S, MONTAZEM A, RAMANATHAN L, PESSIN-MINSLEY M, PFAIL J, STOCK RG, KOGAN R. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 2009: 67: 159-161.
19. MARTINI G, GENNARI L, MERLOTTI D, SALVADORI S, FRANCI MB, CAMPAGNA S, AVANZATI A, DE PAOLA V, VALLEGGI F, NUTI R. Serum opg and rankl levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 2007: 40: 457-463.
20. MARTINI G, GOZZETTI A, GENNARI L, AVANZATI A, NUTI R, LAURIA F. The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma. Haematologica 2006: 91: 1720-1721.
21. MARX RE. Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003: 61: 1115-1117.
22. MEIGS JB, SHRADER P, SULLIVAN LM, MCATEER JB, FOX CS, DUPUIS J, MANNING AK, FLOREZ JC, WILSON PW, D'AGOSTINO SR RB, CUPPLES LA. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008: 359: 2208-2219.
23. REID IR. Osteonecrosis of the jaw: who gets it, and why? Bone 2009: 44: 4-10.
24. RUGGIERO SL, DODSON TB, ASSAEL LA, LANDESBERG R, MARX RE, MEHROTRA B. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009: 67: 2-12.
25. SARASQUETE ME, GARCIA-SANZ R, MARIN L, ALCOCEBA M, CHILLON MC, BALANZATEGUI A, SANTAMARIA C, ROSINOL L, DE LA RUBIA J, HERNANDEZ MT, GARCIA-NAVARRO I, LAHUERTA JJ, GONZALEZ M, SAN MIGUEL JF. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome p450 cyp2c8 in multiple myeloma: a genomewide single nucleotide polymorphism analysis. Blood 2008: 112: 2709-2712.
26. SCHULTZ J, LORENZ P, IBRAHIM SM, KUNDT G, GROSS G, KUNZ M. The functional -443t/c osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-myb transcription factor. Mol Carcinog 2009: 48: 14-23.
27. STANDAL T, BORSET M, SUNDAN A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 2004: 26: 179-184.
28. STYRKARSDOTTIR U, HALLDORSSON BV, GRETARSDOTTIR S, GUDBJARTSSON DF, WALTERS GB, INGVARSSON T, JONSDOTTIR T, SAEMUNDSDOTTIR J, CENTER JR, NGUYEN TV, BAGGER Y, GULCHER JR, EISMAN JA, CHRISTIANSEN C, SIGURDSSON G, KONG A, THORSTEINSDOTTIR U, STEFANSSON K. Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008: 358: 2355-2365.
29. VAN BEEK ER, LOWIK CW, PAPAPOULOS SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogencontaining bisphosphonates on osteoclast precursors. Bone 2002: 30: 64-70.